Announced details
In vitro testing confirmed an inhibitory effect on cell proliferation for a novel molecular target candidate for pancreatic cancer (quantitative efficacy data, including the efficacy rate, are not disclosed).
Already adopted by several major pharmaceutical companies (the number of companies is not disclosed).
FRONTEO will exhibit and give a presentation at the conference. Details of FRONTEO’s capital, personnel and business relationships with Kisaco Research are not disclosed.
Organizer of AI Drug Discovery & Development Summit 2026. Other details are not disclosed.
21 patents obtained in total in Japan, Europe, the United States and South Korea (individual patent numbers and expiration dates are not disclosed)
Boston Marriott Copley Place (Massachusetts, United States)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Official website of AI Drug Discovery & Development Summit 2026; FRONTEO press release dated 13 May 2026
| Item | Details |
|---|---|
| Names of Products / Services Covered | Drug Discovery AI Factory（DDAIF）, KIBIT (Kibit) |
| Counterparty | Kisaco Research (organizer) |
| Counterparty overview | Organizer of AI Drug Discovery & Development Summit 2026. Other details are not disclosed. |
| Relationship with the Company | FRONTEO will exhibit and give a presentation at the conference. Details of FRONTEO’s capital, personnel and business relationships with Kisaco Research are not disclosed. |
| Launch date | 28 October 2026 (scheduled, presentation) / 27–29 October 2026 (scheduled, exhibition and event) |
| Applicable area | Discovery of molecular targets for drug development, Indication discovery, Drug repositioning, Biomarker discovery, Simulation of gene impacts on disease networks (Virtual Experiments) |
| Registration number and expiry date | 21 patents obtained in total in Japan, Europe, the United States and South Korea (individual patent numbers and expiration dates are not disclosed) |
| Location | Boston Marriott Copley Place (Massachusetts, United States) |
| Quantitative Effects | In vitro testing confirmed an inhibitory effect on cell proliferation for a novel molecular target candidate for pancreatic cancer (quantitative efficacy data, including the efficacy rate, are not disclosed). |
| Usage history | Already adopted by several major pharmaceutical companies (the number of companies is not disclosed). |
| Source | Official website of AI Drug Discovery & Development Summit 2026; FRONTEO press release dated 13 May 2026 |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To accelerate the expansion of its life sciences AI business in the United States and communicate DDAIF’s technologies and research findings to pharmaceutical companies and research institutions worldwide.